NovaBay Pharmaceuticals Reports 2019 Second Quarter Net Sales of $1.8 Million

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, reports net sales of $1.8 million for the three months ended June 30, 2019. Avenova sales for the second quarter of 2019 were $1.6 million, a 9% increase from the first quarter of 2019. “The increase in Avenova sales over the prior quarter is particularly impressive given the 67% reduction we made to our sale